JP2018510147A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510147A5 JP2018510147A5 JP2017546200A JP2017546200A JP2018510147A5 JP 2018510147 A5 JP2018510147 A5 JP 2018510147A5 JP 2017546200 A JP2017546200 A JP 2017546200A JP 2017546200 A JP2017546200 A JP 2017546200A JP 2018510147 A5 JP2018510147 A5 JP 2018510147A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fully human
- seq
- cancer
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000003757 neuroblast Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128462P | 2015-03-04 | 2015-03-04 | |
| US62/128,462 | 2015-03-04 | ||
| PCT/US2016/020980 WO2016141328A2 (en) | 2015-03-04 | 2016-03-04 | Antibody therapeutics that bind cd47 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186564A Division JP2020023532A (ja) | 2015-03-04 | 2019-10-10 | Ｃｄ４７に結合する抗体医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510147A JP2018510147A (ja) | 2018-04-12 |
| JP2018510147A5 true JP2018510147A5 (enExample) | 2019-04-04 |
| JP6643350B2 JP6643350B2 (ja) | 2020-02-12 |
Family
ID=56848772
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546200A Active JP6643350B2 (ja) | 2015-03-04 | 2016-03-04 | Ｃｄ４７に結合する抗体医薬 |
| JP2019186564A Withdrawn JP2020023532A (ja) | 2015-03-04 | 2019-10-10 | Ｃｄ４７に結合する抗体医薬 |
| JP2021000870A Active JP7137646B2 (ja) | 2015-03-04 | 2021-01-06 | Ｃｄ４７に結合する抗体医薬 |
| JP2021000869A Active JP7105938B2 (ja) | 2015-03-04 | 2021-01-06 | Ｃｄ４７に結合する抗体医薬 |
| JP2021089081A Withdrawn JP2021121635A (ja) | 2015-03-04 | 2021-05-27 | Ｃｄ４７に結合する抗体医薬 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186564A Withdrawn JP2020023532A (ja) | 2015-03-04 | 2019-10-10 | Ｃｄ４７に結合する抗体医薬 |
| JP2021000870A Active JP7137646B2 (ja) | 2015-03-04 | 2021-01-06 | Ｃｄ４７に結合する抗体医薬 |
| JP2021000869A Active JP7105938B2 (ja) | 2015-03-04 | 2021-01-06 | Ｃｄ４７に結合する抗体医薬 |
| JP2021089081A Withdrawn JP2021121635A (ja) | 2015-03-04 | 2021-05-27 | Ｃｄ４７に結合する抗体医薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10035855B2 (enExample) |
| EP (1) | EP3265125A4 (enExample) |
| JP (5) | JP6643350B2 (enExample) |
| KR (2) | KR102625835B1 (enExample) |
| CN (2) | CN107921121B (enExample) |
| AR (1) | AR103868A1 (enExample) |
| AU (2) | AU2016225993B2 (enExample) |
| IL (2) | IL254321B (enExample) |
| MX (1) | MX385673B (enExample) |
| TW (3) | TWI843184B (enExample) |
| WO (1) | WO2016141328A2 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3411071A4 (en) | 2016-10-20 | 2019-08-28 | I-Mab | NOVEL MONOCLONAL CD47 ANTIBODY AND USES THEREOF |
| US11352425B2 (en) | 2016-11-08 | 2022-06-07 | Absos, Llc | Anti-CD47 antibodies |
| AU2018213718B2 (en) | 2017-01-26 | 2022-08-25 | Zlip Holding Limited | CD47 antigen binding unit and uses thereof |
| EP3589368A4 (en) * | 2017-02-28 | 2021-03-24 | The Board of Trustees of the Leland Stanford Junior University | ANTIFIBROTIC ACTIVITY OF CD47 BLOCKING |
| BR112020001679A2 (pt) | 2017-08-02 | 2020-07-21 | Phanes Therapeutics, Inc. | anticorpos anti-cd47 e usos dos mesmos |
| EP3715377A4 (en) * | 2017-11-20 | 2021-06-02 | Taizhou Mabtech Pharmaceutical Co., Ltd | BIFUNCTIONAL FUSION PROTEIN TARGETING CD47 AND PD-L1 |
| EA202091339A1 (ru) | 2017-12-01 | 2020-10-21 | Сиэтл Дженетикс, Инк. | Антитела против cd47 и их применение для лечения онкологических заболеваний |
| CN110577597B (zh) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
| EP3817769A4 (en) * | 2018-07-05 | 2022-03-30 | Trican Biotechnology Co., Ltd | Human anti-cd47 antibodies and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| MX2021004779A (es) * | 2018-10-31 | 2021-06-08 | I Mab Biopharma Us Ltd | Anticuerpos cd47 novedosos y metodos para usarlos. |
| KR20220047277A (ko) | 2019-07-16 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
| PH12022550835A1 (en) | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
| TW202134280A (zh) | 2019-12-05 | 2021-09-16 | 美商索倫多醫療公司 | 包含抗cd47抗體與腫瘤靶向抗體之組合物及方法 |
| GB201918230D0 (en) | 2019-12-11 | 2020-01-22 | Prec Therapeutics Ltd | Antibodies and their uses |
| CN113004406B (zh) * | 2019-12-20 | 2022-04-26 | 广东菲鹏制药股份有限公司 | 抗cd47抗体及其应用 |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| MX2022009947A (es) | 2020-02-14 | 2022-11-07 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos. |
| EP4127139A1 (en) | 2020-03-27 | 2023-02-08 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| KR20230033647A (ko) | 2020-06-30 | 2023-03-08 | 멘두스 비.브이. | 난소암 백신에서 백혈병 유래 세포의 용도 |
| WO2022109227A1 (en) * | 2020-11-19 | 2022-05-27 | Icahn School Of Medicine At Mount Sinai | Combined cancer therapy of b7-h3 and cd47 immune checkpoint inhbitior and methods of use |
| KR102757518B1 (ko) * | 2020-12-07 | 2025-01-21 | (주)이노베이션바이오 | Cd47에 특이적인 항체 및 이의 용도 |
| EP4274853A4 (en) * | 2021-01-05 | 2024-12-04 | National Institute Of Biological Sciences, Beijing | BISPECIFIC ANTIBODY TARGETING GPC3 AND CD47 |
| JP2024510989A (ja) | 2021-03-12 | 2024-03-12 | メンドゥス・ベスローテン・フェンノートシャップ | ワクチン接種方法及びｃｄ４７遮断薬の使用 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| EP4335872A4 (en) * | 2021-05-07 | 2025-10-29 | Immuneoncia Therapeutics Inc | BI-SPECIFIC ANTIBODY BINDING SPECIFICALLY TO CD47 AND PD-L1 |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4365197A4 (en) * | 2021-06-30 | 2025-05-14 | Innobation Bio Co., Ltd. | Humanized antibody specific to CD47 and pharmaceutical composition containing it for the prevention or treatment of CD47-mediated disease |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| KR102438419B1 (ko) * | 2021-12-01 | 2022-09-01 | 메디포스트(주) | Cd47 과발현 중간엽 줄기세포를 포함하는 폐 질환 예방 또는 치료용 조성물 |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| EP4452415A1 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| HUE069263T2 (hu) | 2022-03-17 | 2025-02-28 | Gilead Sciences Inc | Ikarosz cink-ujj család degradálói és azok alkalmazása |
| JP2025509662A (ja) | 2022-03-24 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| PE20250758A1 (es) | 2022-07-01 | 2025-03-13 | Gilead Sciences Inc | Compuestos de cd73 |
| EP4554628A1 (en) | 2022-07-12 | 2025-05-21 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| KR20250122479A (ko) | 2022-12-22 | 2025-08-13 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| US20240383922A1 (en) | 2023-04-11 | 2024-11-21 | Gilead Sciences, Inc. | KRAS Modulating Compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| KR102891091B1 (ko) * | 2024-05-22 | 2025-11-27 | 주식회사 이뮨온시아 | 항-cd47 항체를 이용한 진행성 또는 전이성 고형암의 치료 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138496B2 (en) * | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| EP2111869A1 (en) * | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| CA3138956A1 (en) * | 2010-05-14 | 2011-11-17 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
| MY169341A (en) * | 2012-02-06 | 2019-03-21 | Inhibrx Inc | Cd47 antibodies and methods of use thereof |
| PL2900694T3 (pl) * | 2012-09-27 | 2018-12-31 | Merus N.V. | Dwuswoiste przeciwciała igg jako aktywatory komórek t |
| PT2925782T (pt) * | 2012-12-03 | 2020-04-22 | Novimmune Sa | Anticorpos anti-cd47 e métodos de utilização destes |
| BR112015013431A2 (pt) * | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
| EP2953643B1 (en) * | 2013-02-06 | 2023-02-22 | Inhibrx, Inc. | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
-
2016
- 2016-03-04 AU AU2016225993A patent/AU2016225993B2/en active Active
- 2016-03-04 CN CN201680024600.9A patent/CN107921121B/zh active Active
- 2016-03-04 TW TW111131339A patent/TWI843184B/zh active
- 2016-03-04 AR ARP160100592A patent/AR103868A1/es unknown
- 2016-03-04 EP EP16759606.3A patent/EP3265125A4/en active Pending
- 2016-03-04 US US15/061,771 patent/US10035855B2/en active Active
- 2016-03-04 JP JP2017546200A patent/JP6643350B2/ja active Active
- 2016-03-04 MX MX2017011329A patent/MX385673B/es unknown
- 2016-03-04 CN CN202210050901.6A patent/CN114380912B/zh active Active
- 2016-03-04 KR KR1020177028115A patent/KR102625835B1/ko active Active
- 2016-03-04 TW TW105106782A patent/TWI719966B/zh active
- 2016-03-04 TW TW110105132A patent/TWI778518B/zh active
- 2016-03-04 WO PCT/US2016/020980 patent/WO2016141328A2/en not_active Ceased
- 2016-03-04 KR KR1020247000720A patent/KR102850868B1/ko active Active
-
2017
- 2017-09-04 IL IL254321A patent/IL254321B/en unknown
-
2019
- 2019-10-10 JP JP2019186564A patent/JP2020023532A/ja not_active Withdrawn
-
2020
- 2020-12-21 AU AU2020294159A patent/AU2020294159B2/en active Active
-
2021
- 2021-01-06 JP JP2021000870A patent/JP7137646B2/ja active Active
- 2021-01-06 JP JP2021000869A patent/JP7105938B2/ja active Active
- 2021-05-27 JP JP2021089081A patent/JP2021121635A/ja not_active Withdrawn
- 2021-11-09 IL IL287958A patent/IL287958B2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510147A5 (enExample) | ||
| JP2021054859A5 (enExample) | ||
| JP2018510865A5 (enExample) | ||
| JP2018510151A5 (enExample) | ||
| JP2018508509A5 (enExample) | ||
| JP2017176174A5 (enExample) | ||
| JP2012116856A5 (enExample) | ||
| JP2014509837A5 (enExample) | ||
| JP2018193386A5 (enExample) | ||
| JP2014205674A5 (enExample) | ||
| WO2016207304A8 (en) | Monoclonal anti-il-1racp antibodies | |
| JP2012176953A5 (enExample) | ||
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| JP2009521474A5 (enExample) | ||
| JP2018536393A5 (enExample) | ||
| JP2017048240A5 (enExample) | ||
| JP2011511773A5 (enExample) | ||
| JP2018504105A5 (enExample) | ||
| CL2010000096A1 (es) | Anticuerpo monoclonal o una porción que se une al antígeno del mismo que se une a alk-1, molécula de acido nucleico codificante; composición farmaceutica que lo comprende; uso de dicho anticuerpo para preparar un medicamento útil para inhibir la angiogénesis en un mamifero. (div.sol.2333-06). | |
| EA202090800A1 (ru) | Новые анти-cd3-эпсилон антитела | |
| JP2010506596A5 (enExample) | ||
| JP2016512223A5 (enExample) | ||
| JP2013500715A5 (enExample) | ||
| JP2015504421A5 (enExample) | ||
| RU2015100231A (ru) | Способ отбора и получения селективных и мультиспецифических терапевтических молекул с заданными свойствами, включающих по меньшей мере две различные нацеливающие группировки, и их применения |